NICE, together with NHS England, remains committed to working with the company to try to reach a long-term deal that will give access to cerliponase alfa to all eligible people after that time.

This month we published a modular update to our health technology evaluations manual focusing on how we consider the effect of health technologies on health inequalities. The update is designed to ...

Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer [ID6339] Draft guidance Technology appraisal guidance 2 June 2025 Metabolic Dysfunction-Associated ...

There is a simple discount patient access scheme for brentuximab vedotin. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

There is a simple discount patient access scheme for erdafitinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Erdafitinib (Balversa, Johnson & Johnson) is indicated for 'the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations ...

There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee C. Committee members are asked to declare any interests in the technology being ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

You can now comment on this draft scope. The scope defines what the guideline will (and will not) cover. NICE is transforming to deliver more timely, relevant and impactful guidance while maintaining ...